News
-
-
-
COMMUNIQUÉ DE PRESSE
ViferaXS Raises €12 Million to Advance Phase II Trial in Chronic Lymphocytic Leukemia and Expand Its Oncology Pipeline
ViferaXS raises €12 million for Phase II trial in Chronic Lymphocytic Leukemia, advancing peptide-based cancer immunotherapy. SPRIND and Huma lead funding round